BioInvent International AB

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Companys validated, proprietary F.I.R.S.TTM technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Companys own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well...

Bioinvent international ab operates in the Biotechnology industry.

Bioinvent international ab's revenue is 1m - 10m

Bioinvent international ab has 51 - 200 employees.